Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Idea to Innovation

McMaster University

$14,775.00

Smart nanotech sensors using human red blood cell membranes for fast blood testing

EF 2016-17

Résumé
We have developed a novel blood test to detect hemolytic activity using an electrochemical sensor wherein anano-structured electrode is coated with real human red blood cell membranes (HBLOC sensor). A droplet ofblood from a patient sample is applied onto the HBLOC sensor and detection of a leak current across the redblood cell membranes is indicative of membrane damage and rupture. An electronic reading proportional tohemolysis activity is available within minutes. We believe the HBLOC sensor technology will have significantadvantages with respect to speed and cost over current hemolysis tests and could become routinely used forclinical testing and pre-clinical drug development. Hemolysis, i.e., the rupturing of red blood cells and therelease of their contents into surrounding fluids, is a common threat in health care and a toxicity liability fordrug development. Hemolysis can occur as a result of bacterial infections (sepsis), or induced by drugs, knownas toxic hemolysis, through direct toxicity by the drug or its metabolite. Hemolysis testing during drugdevelopment is recommended by the U.S. Food and Drug Administration (FDA), and routinely screened duringpre-clinical development. Sepsis is a serious and difficult to treat medical condition that is a leading cause ofdeath in hospital intensive care units [1]. Every year, more than a million Americans are affected [2] andestimated that between 28 and 50 percent of these patients die [3]. Sepsis also affects an estimated 30,000Canadians each year, and over one-third of these will die if not treated quickly and appropriately. The numberof sepsis cases per year is rising mainly due to an aging population, the increased longevity of people withchronic diseases and the spread of antibiotic-resistant organisms. Treatment for sepsis often involves aprolonged stay in the intensive care unit and complex therapies, leading to high costs. The Agency forHealthcare Research and Quality lists sepsis as the most expensive condition treated in U.S. hospitals, costingmore than $20 billion in 2011 [4,5,6]. One of the major challenges in combating sepsis is early diagnosis. Earlyintervention before sepsis develops would have a profound effect on survival rates and healthcare costs.
Programme
Idea to Innovation
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
505834-2017
Name nom
Rheinstadter, Maikel
Department département
Physics and Astronomy
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2017
Award amount
14775
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
3113
Research subject group en
Physics
Research subject group fr
Physique
Research subject en
Biophysics
Research subject fr
Biophysique
Partie
1
Nb partie
1
Application title
Smart nanotech sensors using human red blood cell membranes for fast blood testing
Keyword
NSERC
Application summary
We have developed a novel blood test to detect hemolytic activity using an electrochemical sensor wherein anano-structured electrode is coated with real human red blood cell membranes (HBLOC sensor). A droplet ofblood from a patient sample is applied onto the HBLOC sensor and detection of a leak current across the redblood cell membranes is indicative of membrane damage and rupture. An electronic reading proportional tohemolysis activity is available within minutes. We believe the HBLOC sensor technology will have significantadvantages with respect to speed and cost over current hemolysis tests and could become routinely used forclinical testing and pre-clinical drug development. Hemolysis, i.e., the rupturing of red blood cells and therelease of their contents into surrounding fluids, is a common threat in health care and a toxicity liability fordrug development. Hemolysis can occur as a result of bacterial infections (sepsis), or induced by drugs, knownas toxic hemolysis, through direct toxicity by the drug or its metabolite. Hemolysis testing during drugdevelopment is recommended by the U.S. Food and Drug Administration (FDA), and routinely screened duringpre-clinical development. Sepsis is a serious and difficult to treat medical condition that is a leading cause ofdeath in hospital intensive care units [1]. Every year, more than a million Americans are affected [2] andestimated that between 28 and 50 percent of these patients die [3]. Sepsis also affects an estimated 30,000Canadians each year, and over one-third of these will die if not treated quickly and appropriately. The numberof sepsis cases per year is rising mainly due to an aging population, the increased longevity of people withchronic diseases and the spread of antibiotic-resistant organisms. Treatment for sepsis often involves aprolonged stay in the intensive care unit and complex therapies, leading to high costs. The Agency forHealthcare Research and Quality lists sepsis as the most expensive condition treated in U.S. hospitals, costingmore than $20 billion in 2011 [4,5,6]. One of the major challenges in combating sepsis is early diagnosis. Earlyintervention before sepsis develops would have a profound effect on survival rates and healthcare costs.